D-0640-2021 Class II Terminated

Recalled by VIONA PHARMACEUTICALS INC — Cranford, NJ

FDA drug recall D-0640-2021 was initiated by VIONA PHARMACEUTICALS INC on Jun 1, 2021 and is designated Class II. Reason for recall: CGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit. The recall status is terminated (terminated May 31, 2023). Affected quantity: 21240 bottles.

Recall details

Product Type
Drugs
Report Date
Jun 30, 2021
Initiation Date
Jun 1, 2021
Termination Date
May 31, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
21240 bottles

Product description

Metformin Hydrochloride Extended-Release Tablets, USP 750 mg, 100 Tablets, Rx only, Manufactured by: Cadila Healthcare Ltd. Ahmedabad, India. Distributed by: Viona Pharmaceuticals Inc. Cranford, NJ 07016 NDC 72578-036-01

Reason for recall

CGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.

Distribution pattern

Nationwide in the US

Code information

Lot M915601 & M915602, Oct 2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0640-2021
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0640-2021. Report a data issue: hello@regdatalab.com.